NCT04600999已完成3 期
An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients With Mild Pneumonia - An Open-label Randomized Controlled Study -
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 5
- 主要终点
- Time to improvement in body temperature
研究概览
简要总结
To verify that the efficacy of favipiravir exceeds that of the actual supportive care (symptomatic therapy) in SARS-CoV-2 infected patients (COVID-19 patients) with mild pneumonia, using the time required to improve clinical symptoms as the primary endpoint.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 74 years (at the time of informed consent)
- •Male or female
- •Patients who meet all of the following three criteria at the time of enrolment:
- •SARS-CoV-2-positive patients as measured by rtPCR by nasopharyngeal sampling
- •Moderate patients with radiological evidence of pneumonia in the lung at the time of enrolment (RTG, CT, or UH), clearly described by the radiologist following the imaging examination. (The diagnosis of the finding should clearly include the presence of pneumonia to any extent, localization, and extent)
- •Body temperature 37,5°C or more
- •Patient requires hospitalization during the treatment period (obligation to stay in the hospital for whole treatment period, 14 days)
- •For premenopausal females, patients who have been confirmed to be negative on a pregnancy test before administration of the study drug
- •Signed informed consent by the patient or by the legal representative -
排除标准
- •Body temperature of 37.5 °C or higher for more than 10 days after the onset of elevated body temperature
- •Patients with SpO2 less than 95%
- •Patient requires supportive oxygen therapy
- •Patients who show increased procalcitonin levels before the start of the study drug administration and are suspected to have concurrent bacterial infection
- •Patients with proven concomitant systematic fungal infection prior to initiation of study drug.
- •Patients with concurrent congestive heart failure (NYHA III-IV)
- •Patients with severe hepatic impairment equivalent to Grade C on Child-Pugh classification
- •Patient with renal impairment requiring dialysis.
- •Patients with disturbed consciousness such as disturbed orientation.
- •Pregnant or possibly pregnant patients.
- •Female patients who are woman of childbearing potential and unable to consent to the use of dual contraception from the start of favipiravir administration to 30 days after the end of favipiravir administration. Dual contraception is a combination of two of the following: Barrier method of contraception: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide; IUD; Hormone-based contraceptive; Tubal ligation
- •Male patients whose are unable to consent to the use of the barrier method of contraception (condom) from the start of favipiravir administration to 90 days after the end of favipiravir administration. Male patients who are planning to donate sperm from the start up until 90 days after the end of favipiravir administration.
- •Female patients who intend to breastfeed from the start of favipiravir administration until 14 days after discontinuation of favipiravir administration
- •Patients with herditary xanthinuria
- •Patients who have hyperuricemia (> 1 mg/dL) or xanthine urinary calculi
- •Patients with a history of gout or on treatment for gout or hyperuricemia
- •Patients receiving immunosuppressants
- •Patients who received interferon-alpha or drugs with reported antiviral activity against SARS-CoV-2 (hydroxychloroquine sulfate, chloroquine phosphate, lopinavir-ritonavir combination, ciclesonide, nafamostat mesylate, camostat mesylate, remdesivir, etc.) within 9 days after fever onset (37.5°C or more)
- •Patients in whom this episode of infection is a recurrence or a reinfection with the SARS-CoV-2 infection
- •Patients who have previously been treated with favipiravir (T-705a)
- •Other patients judged ineligible by the investigator, sub-investigator, or assigned physician.
研究组 & 干预措施
Group Avigan
Experimental
Favipiravir from Day1 + Supportive care (symptomatic therapy) a regimen of 3600 mg (1800 mg twice a day orally) loading dose on Day1 followed by 1600 mg maintenance dose (800 mg twice a day orally) on Day2 to Day14.
干预措施: Favipiravir (Drug)
结局指标
主要结局
Time to improvement in body temperature
时间窗: 9 month
Time to improvement in SpO2
时间窗: 9 month
Time to improvement in chest imaging findings
时间窗: 9 month
Time to improvement in negative SARS-CoV-2
时间窗: 9 month
次要结局
- (1) Changes in patient status on a 5-point scale(9 month)
- (3) SARS-CoV-2 virus genome clearance rate(9 month)
- (2) Changes in the level of SARS-CoV-2 viral genome(9 month)
- (4) Duration of pyrexia(9 month)
- (6) Changes in NEWS (National Early Warning Score)(9 month)
- (7) Changes in chest imaging findings on Days 4,7,10,13,16,19,22,25,28.(Changes in chest imaging findings will be collected and checked on Days 4,7,10,13,16,19,22,25,28, the data will be analyzied at 9. month.)
- (8) Percentage of patients requiring adjuvant oxygen therapy(9 month)
- (8) Adjuvant oxygen therapy average duration(9 month)
- (9) Percentage of patients requiring mechanical ventilation therapy(9 month)
- (5) Changes in clinical symptoms(9 month)
- (9)Adjuvant oxygen therapy average durationduration(9 month)
研究者
研究点 (5)
Loading locations...
相似试验
招募中
3 期
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84
已完成
2 期
Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19Sars-CoV2COVID-19NCT04346628Stanford University149
Unknown
4 期
Favipiravir in Hospitalized COVID-19 PatientsCOVID-19NCT04359615Shahid Beheshti University of Medical Sciences40
Unknown
3 期
Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19COVID-19NCT04336904Giuliano Rizzardini100
终止
2 期
Study to Assess the Efficacy and Safety of Favipiravir-HUSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)NCT04940871University of Pecs1